Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$33.72 - $48.82 $13.8 Million - $20 Million
409,955 Added 81.02%
915,974 $33.1 Million
Q1 2024

May 13, 2024

BUY
$14.91 - $49.14 $7.54 Million - $24.9 Million
506,019 New
506,019 $21.8 Million

Others Institutions Holding VERA

About Vera Therapeutics, Inc.


  • Ticker VERA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 27,042,300
  • Market Cap $1.24B
  • Description
  • Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with ...
More about VERA
Track This Portfolio

Track Artal Group S.A. Portfolio

Follow Artal Group S.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

News

Stay updated on Artal Group S.A. with notifications on news.